Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
REC-01 by Purec for Hypophosphatasia: Likelihood of Approval
REC-01 is under clinical development by Purec and currently in Phase II for Hypophosphatasia. According to GlobalData, Phase II drugs...